Harari, Alexandre 
; Bart, Pierre-Alexandre ; Stöhr, Wolfgang ; Tapia, Gonzalo ; Garcia, Miguel ; Medjitna-Rais, Emmanuelle ; Burnet, Séverine ; Cellerai, Cristina ; Erlwein, Otto ; Barber, Tristan ; Moog, Christiane ; Liljestrom, Peter ; Wagner, Ralf ; Wolf, Hans ; Kraehenbuhl, Jean-Pierre ; Esteban, Mariano ; Heeney, Jonathan ; Frachette, Marie-Joelle ; Tartaglia, James ; McCormack, Sheena ; Babiker, Abdel ; Weber, Jonathan ; Pantaleo, Giuseppe
; Bart, Pierre-Alexandre ; Stöhr, Wolfgang ; Tapia, Gonzalo ; Garcia, Miguel ; Medjitna-Rais, Emmanuelle ; Burnet, Séverine ; Cellerai, Cristina ; Erlwein, Otto ; Barber, Tristan ; Moog, Christiane ; Liljestrom, Peter ; Wagner, Ralf ; Wolf, Hans ; Kraehenbuhl, Jean-Pierre ; Esteban, Mariano ; Heeney, Jonathan ; Frachette, Marie-Joelle ; Tartaglia, James ; McCormack, Sheena ; Babiker, Abdel ; Weber, Jonathan ; Pantaleo, Giuseppe 
Zusammenfassung
The EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen comprising recombinant DNA and the poxvirus vector NYVAC, both expressing a common immunogen consisting of Env, Gag, Pol, and Nef polypeptide domain from human immunodeficiency virus (HIV)-1 clade C isolate, CN54. 40 volunteers were randomized to receive DNA C or nothing on day 0 and at week 4, ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Altmetric